Novo Nordisk AS (NVO)
110.03
-1.91
(-1.71%)
USD |
NYSE |
Nov 04, 12:58
Novo Nordisk Enterprise Value: 497.34B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 497.34B |
| October 31, 2024 | 497.38B |
| October 30, 2024 | 503.12B |
| October 29, 2024 | 497.52B |
| October 28, 2024 | 499.21B |
| October 25, 2024 | 503.75B |
| October 24, 2024 | 506.20B |
| October 23, 2024 | 514.30B |
| October 22, 2024 | 517.55B |
| October 21, 2024 | 521.38B |
| October 18, 2024 | 524.76B |
| October 17, 2024 | 525.34B |
| October 16, 2024 | 524.49B |
| October 15, 2024 | 523.51B |
| October 14, 2024 | 532.28B |
| October 11, 2024 | 533.44B |
| October 10, 2024 | 522.30B |
| October 09, 2024 | 519.94B |
| October 08, 2024 | 520.83B |
| October 07, 2024 | 523.36B |
| October 04, 2024 | 511.57B |
| October 03, 2024 | 511.42B |
| October 02, 2024 | 517.65B |
| October 01, 2024 | 524.46B |
| September 30, 2024 | 529.18B |
| Date | Value |
|---|---|
| September 27, 2024 | 536.70B |
| September 26, 2024 | 552.48B |
| September 25, 2024 | 564.28B |
| September 24, 2024 | 557.56B |
| September 23, 2024 | 549.81B |
| September 20, 2024 | 566.77B |
| September 19, 2024 | 599.61B |
| September 18, 2024 | 587.05B |
| September 17, 2024 | 586.79B |
| September 16, 2024 | 608.60B |
| September 13, 2024 | 609.04B |
| September 12, 2024 | 607.56B |
| September 11, 2024 | 601.19B |
| September 10, 2024 | 576.93B |
| September 09, 2024 | 586.41B |
| September 06, 2024 | 582.99B |
| September 05, 2024 | 581.90B |
| September 04, 2024 | 598.11B |
| September 03, 2024 | 605.81B |
| August 30, 2024 | 618.72B |
| August 29, 2024 | 611.44B |
| August 28, 2024 | 597.91B |
| August 27, 2024 | 601.03B |
| August 26, 2024 | 601.56B |
| August 23, 2024 | 609.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
113.82B
Minimum
Mar 20 2020
656.85B
Maximum
Jun 25 2024
295.58B
Average
243.80B
Median
Dec 23 2021
Enterprise Value Benchmarks
| Evaxion Biotech AS | 14.87M |
| Amgen Inc | 222.98B |
| Viking Therapeutics Inc | 7.191B |
| Adaptimmune Therapeutics PLC | 14.71M |
| Genfit SA | 294.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.894B |
| Revenue (Quarterly) | 9.824B |
| Total Expenses (Quarterly) | 6.081B |
| EPS Diluted (Quarterly) | 0.6481 |
| Gross Profit Margin (Quarterly) | 84.90% |
| Profit Margin (Quarterly) | 29.46% |
| Earnings Yield | 2.65% |
| Operating Earnings Yield | 3.29% |
| Normalized Earnings Yield | 2.649 |